UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker

Annals of neurology, 2021-05, Vol.89 (5), p.1001-1010

2021

Volltextzugriff (PDF)

The effect of burosumab on intact and C‐terminal FGF23 measurements

Clinical endocrinology (Oxford), 2023-08, Vol.99 (2), p.152-157

2023

Volltextzugriff (PDF)

Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation

Liver transplantation, 2015-05, Vol.21 (5), p.599-606

2015

Volltextzugriff (PDF)

Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis

European journal of neurology, 2022-10, Vol.29 (10), p.2905-2912

2022

Volltextzugriff (PDF)

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

Alzheimer's & dementia, 2022-06, Vol.18 (6), p.1128-1140

2022

Volltextzugriff (PDF)

Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers

Alzheimer's & dementia, 2024-05, Vol.20 (5), p.3657-3658

2024

Volltextzugriff (PDF)

Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges

Clinical chemistry (Baltimore, Md.), 2011-06, Vol.57 (6), p.833-840

2011

Volltextzugriff (PDF)

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2024-01, Vol.16 (1), p.e12545-n/a

2024

Volltextzugriff (PDF)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2021, Vol.13 (1), p.e12190-n/a

2021

Volltextzugriff (PDF)

Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance

Alzheimer's & dementia, 2024-05, Vol.20 (5), p.3661-3663

2024

Volltextzugriff (PDF)

Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2023-07, Vol.15 (3), p.e12461-n/a

2023

Volltextzugriff (PDF)

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays

Alzheimer's & dementia, 2022-04, Vol.18 (4), p.635-644

2022

Volltextzugriff (PDF)

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

Alzheimer's & dementia, 2022-04, Vol.18 (4), p.602-611

2022

Volltextzugriff (PDF)

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes

Alzheimer's research & therapy, 2021-12, Vol.13 (1), p.199-199, Article 199

2021

Volltextzugriff (PDF)

Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders

Endocrine practice, 2023-03, Vol.29 (3), p.193-198

2023

Volltextzugriff (PDF)

Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays

Alzheimer's & dementia, 2024-09, Vol.20 (9), p.6506-6516

2024

Volltextzugriff (PDF)

Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals

Alzheimer's & dementia, 2024-03, Vol.20 (3), p.2143-2154

2024

Volltextzugriff (PDF)

Vascular risk, gait, behavioral, and plasma indicators of VCID

Alzheimer's & dementia, 2024-02, Vol.20 (2), p.1201-1213

2024

Volltextzugriff (PDF)

Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET

Alzheimer's & dementia, 2024-02, Vol.20 (2), p.1225-1238

2024

Volltextzugriff (PDF)

Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology

Alzheimer's & dementia : diagnosis, assessment & disease monitoring, 2022, Vol.14 (1), p.e12291-n/a

2022

Volltextzugriff (PDF)

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Alzheimer's & dementia, 2024-04, Vol.20 (4), p.2485-2496

2024

Volltextzugriff (PDF)

United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin

Clinical chemistry (Baltimore, Md.), 2017-09, Vol.63 (9), p.1489-1496

2017

Volltextzugriff (PDF)

c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis

The EMBO journal, 2002-07, Vol.21 (14), p.3704-3714

2002

Volltextzugriff (PDF)

Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD

BMC nephrology, 2021-03, Vol.22 (1), p.1-114, Article 114

2021

Volltextzugriff (PDF)

1 – 25 von 175

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(168)
Mit Volltextzugriff
(147)

Publikationsform

Artikel
(172)
Buchkapitel
(3)

Sprache

Englisch
(175)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker

The effect of burosumab on intact and C‐terminal FGF23 measurements

Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation

Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis

Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities

Importance of cerebrospinal fluid (CSF) collection protocol for the accurate diagnosis of Alzheimer's disease when using CSF biomarkers

Analysis of Circulating MicroRNA: Preanalytical and Analytical Challenges

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status

Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance

Plasma-derived biomarkers of Alzheimer's disease and neuropsychiatric symptoms: A community-based study

Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays

Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes

Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders

Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays

Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals

Vascular risk, gait, behavioral, and plasma indicators of VCID

Modeling the temporal evolution of plasma p‐tau in relation to amyloid beta and tau PET

Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology

Plasma biomarkers of Alzheimer's disease in the continuum of dementia with Lewy bodies

Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

United States and European Multicenter Prospective Study for the Analytical Performance and Clinical Validation of a Novel Sensitive Fully Automated Immunoassay for Calcitonin

c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis

Hyperphosphatemia with elevated serum PTH and FGF23, reduced 1,25(OH)2D and normal FGF7 concentrations characterize patients with CKD

Suchergebnisse filtern